Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NYU Langone Health
With
Trod Medical N.V.
Age
40–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Subject Population:
Men 40-80 years of age
Diagnosis of adenocarcinoma of the prostate, confirmed by TransRectal Ultrasound (TRUS) biopsy
No prior treatment for prostate cancer
Prostate Cancer Clinical Stage T1c
Prostate-specific antigen (PSA)\<10 ng/ml (this will be the PSA level prompting the initial prostate biopsy)
Declined all standard treatment options
Pre-enrollment biopsy parameters:
Minimum of 12 biopsy cores
Gleason 6 (3+3) or 7 (3+4)
Final enrollment biopsy parameters after fusion biopsy:
12 standard biopsy cores plus targeted regions based upon MRI
Gleason 6 (3+3) or 7 (3+4)
No demonstrated cancer diameter \>1.2 cm
History of transurethral resection of prostate (TURP) or other similar procedures transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA)
History of prior pelvic radiation
Men who have received any hormonal manipulation (antiandrogens; luteinizing hormone-releasing hormone (LHRH)-agonist; 5-alpha-reductase inhibitors) within the previous 12 months
Contraindication for Multiparametric-MRI
You may not be if
Histology other than adenocarcinoma
Clareo Health | MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer
